Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. The company’s scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive and, as a result, it believes these cells can be applied across multiple “ischemic” conditions. Cytori’s therapies are made available to the physician and patient at the point-of-care by the company’s proprietary technologies and products, including the Celution System product family. For more information, visit the company’s website at www.cytori.com.